A new injectable treatment for opioid addiction showed promise in a late-stage study, according to The Wall Street Journal. The study involved weekly and monthly injections of buprenorphine for the treatment of moderate to severe opioid use disorder.
Buprenorphine is currently available as a tablet and as film that dissolves in the mouth. According to Braeburn Pharmaceuticals, which makes the new treatment, the study included 428 patients. It showed the injections were superior to the tablet treatment.